Compare IDEXX Laboratories, Inc. (IDXX) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs LyondellBasell Industries NV — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while LyondellBasell Industries NV trades at $60.03 (market cap $19.49B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.1× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and LyondellBasell Industries NV for 87 Days on average.
| IDXX | LYB | |
|---|---|---|
Market Cap | $40.43B | $19.49B |
Volume | 692,164 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $82.38 |
52-Week Low | $504.70 | $42.28 |
Typical Hold Time | 46 Days | 87 Days |
Enterprise Value | $41.32B | $31.08B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
LyondellBasell (LYB) trades at $60.36, up 3.19% today, showing mixed signals with a bearish technical outlook but strong recent earnings beats. The company faces fundamental challenges with negative net income margins (-1.13%) and ROE (-3.19%) despite revenue stabilization around $31B. Recent Q2 2026 earnings significantly exceeded expectations at $4.30 EPS versus $3.44 expected, driven by operational improvements and favorable market conditions in the chemicals sector.
LYB presents a cautious opportunity with analyst consensus price target of $69.38 (15% upside) but carries significant risk from cyclical industry pressures and declining cash flow trends. The dividend yield remains attractive but coverage concerns persist amid capital expenditure constraints. Investors should weigh strong analyst buy ratings (45%) against technical resistance near $61-62 and ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
